A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Mar 2025 According to a Hudson Therapeutics media release, to prepare for this next trial phase, Shaperon has partnered with leading US clinical research institutions,including Cahaba Dermatology Skin Health Center and L.A.Universal Research Center, as well as 8 additional clinical trial sites across the US.The trial will also be conducted in South Korea, at Seoul National University Hospital, Bundang Seoul National University Hospital, Severance Hospital,and Sejong Chungnam National University Hospital.
10 Mar 2025 Results presented in a Hudson Therapeutics media release
10 Mar 2025 According to a Hudson Therapeutics media release, dosing expected to conclude by December 2025. Final clinical data will be available in the first half of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com